SEC Form 4 · accession 0001213900-26-098038
CollPlant Biotechnologies Ltd · CLGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eran Rotem
Officer — Deputy CEO and CFO
Period of report
Sep 3, 2026
Accepted (ET)
Sep 8, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001631487
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2,F3 | Sep 3, 2026 | A | 510,372 | $0.00 | A | 516,372 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The Reporting Person was granted restricted share units ("RSUs"), each represents a contingent right to receive one ordinary share, no par value per share, of the Issuer ("Ordinary Shares"). The RSUs vest in accordance with the following vesting schedule: Thirty percent (30%) of the RSUs vest on September 3, 2027, and the remaining seventy percent (70%) vest in equal installments every three months thereafter over the following four years, such that the RSUs will be fully vested on September 3, 2031, subject to the Reporting Person's continued service to the Company through each vesting date.
- F2Effective as of September 4, 2026, the Issuer effected a 1-for-10 reverse stock split of its Ordinary Shares (the 'Reverse Stock Split'). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
- F3The total reported in Column 5 includes (i) 510,372 newly-awarded RSUs, (ii) 3,375 Ordinary Shares, and (iii) 2,625 previously-awarded RSUs.